CLINICAL MICROBIOLOGY REVIEWS, Apr. 2008, p. 291–304 0893-8512/08/$08.00⫹0 doi:10.1128/CMR.00030-07 Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Vol. 21, No. 2
Human Bocavirus: Passenger or Pathogen in Acute Respiratory Tract Infections? Oliver Schildgen,1‡* Andreas Mu ¨ller,2 Tobias Allander,3 Ian M. Mackay,4,5 2 Sebastian Vo ¨lz, Bernd Kupfer,2‡ and Arne Simon1 Institute for Virology, University of Bonn, Bonn, Germany1; Children’s Hospital Medical Center, University of Bonn, Bonn, Germany2; Karolinska Institutet, Department of Microbiology Tumor and Cell Biology, Laboratory for Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden3; Queensland Paediatric Infectious Diseases Laboratory, Sir Albert Sakzewski Virus Research Centre, Royal Children’s Hospital, Brisbane, Australia4; and Clinical Medical Virology Centre, University of Queensland, Brisbane, Australia5 INTRODUCTION .......................................................................................................................................................291 TAXONOMY ...............................................................................................................................................................292 BIOLOGY OF BOCAVIRUS.....................................................................................................................................292 LABORATORY DIAGNOSIS....................................................................................................................................292 HBoV AND RESPIRATORY TRACT DISEASE ....................................................................................................293 Possible Role of Coinfections ................................................................................................................................295 EPIDEMIOLOGY .......................................................................................................................................................295 Prevalence of HBoV ................................................................................................................................................297 Seasonal Distribution of HBoV Detection...........................................................................................................297 Transmission ...........................................................................................................................................................298 CLINICAL OBSERVATIONS ...................................................................................................................................299 Limitations of Available Studies...........................................................................................................................300 Symptoms Presumably Associated with HBoV Infection ..................................................................................300 Chest Radiography Findings.................................................................................................................................301 HBoV and Acute Wheezing....................................................................................................................................301 HBoV in Immunocompromised Patients .............................................................................................................301 Laboratory Results for HBoV-Infected Patients.................................................................................................301 TREATMENT AND PREVENTION.........................................................................................................................302 CONCLUSIONS AND FURTHER RESEARCH ....................................................................................................302 ACKNOWLEDGMENTS ...........................................................................................................................................302 REFERENCES ............................................................................................................................................................302 viruses were not sought using PCR, and several other known respiratory pathogens, including human rhinoviruses (HRVs) and human coronaviruses (HCoVs), were not sought by any means. The fact that HBoV was not detected randomly in the material but was detected significantly more often in the absence of other detected viruses nevertheless suggested that HBoV may be a causative agent of previously unexplained respiratory tract disease. All 14 children without codetection had been admitted to an inpatient medical treatment center after presenting with symptoms of cough and fever during the previous 1 to 4 days. Since the first report, the worldwide presence of HBoV in children with ARTI has been confirmed by over 40 studies. However, most published studies describe virus prevalence and were not designed to address the issue of disease association. Thus, to date, the evidence for an association between HBoV and respiratory tract disease is incomplete. The many prevalence studies have found an unusually high number of coinfections where HBoV occurs simultaneously with other viruses, making the association of HBoV with disease more complex. Moreover, Koch’s revised postulates cannot be applied to HBoV, since neither a method for HBoV culture nor an animal model of infection has been established (26). This situation applies to most newly identified viruses, including HCoVNL63 (72) and HCoV-HKU1 (82), polyomaviruses KI (2) and
INTRODUCTION Human bocavirus (HBoV) was first described in September 2005 by Tobias Allander and coworkers at the Karolinska University Hospital, Stockholm, Sweden (2). The finding resulted from the intensive investigation of two chronologically distinct pools of nasopharyngeal aspirates (NPAs) obtained from mostly pediatric patients with suspected acute respiratory tract infections (ARTIs). Thus, HBoV joined the ranks of viruses colloquially termed “respiratory viruses,” which are detected predominantly in patients with infection of the respiratory tract. A random PCR-cloning-sequencing approach was employed. In the original study, HBoV DNA was subsequently identified in 17 out of 540 NPAs (3.1%). Coincident detection of another virus occurred for three patients (17.6% of positive patients), including two instances of human respiratory syncytial virus (RSV) and one detection of human adenovirus (AdV) (2). No other viruses were detected in 14 of 17 HBoVpositive symptomatic patients, at a glance suggesting a high occurrence of sole detections. However, common respiratory
* Corresponding author. Mailing address: Institute for Virology, SigmundFreud-Str. 25, D-53105 Bonn, Germany. Phone: 49-(0)228-28711186. Fax: 49-(0)228-28714433. E-mail:
[email protected]. ‡ These authors contributed equally to this work. 291
292
SCHILDGEN ET AL.
WU (29), and the HRVs, HRV-QPM, NAT-001, and NAT045 (51). Many newly identified viruses have probably remained undetected until now exactly because of their inability to replicate in vitro under standard conditions and may therefore never fulfill Koch’s postulates. Well-designed clinical studies will be needed to confirm the causative role of a virus for a disease, as proposed by Fredericks and Relman (26). A number of these studies will be required before a causative role for HBoV in respiratory tract disease can be established. This review includes all HBoV studies published online up to early 2007, includes prospectively collected data from the winter season from 2005 to 2006 (74), and discusses virological and clinical aspects of this newly identified virus. TAXONOMY HBoV is a putative member of the family Parvoviridae (subfamily Parvovirinae, genus Bocavirus). Until the identification of HBoV, human parvovirus B19 (B19V) (subfamily Parvovirinae, genus Erythrovirus) had been the only human pathogen in the family. B19V is the causative agent of fifth disease, hydrops fetalis (53), and aplastic anemia, in particular in patients with preexisting hematopoietic disease (20, 21, 23, 30, 42, 76). HBoV was classified as a bocavirus based on genomic structure and amino acid sequence similarity shared with the namesake members of the genus, bovine parvovirus (13) and canine minute virus (9, 65). Consequently, the first human member of this virus genus has been provisionally termed human bocavirus (2, 52). Other human parvoviruses of interest include the newly identified human parvovirus 4 (PARV4), which is currently unclassified, and the five current species of human adeno-associated viruses (AAV), which reside in the genus Dependovirus. PARV4 is detected in human plasma used in the manufacture of medicinal products, but no pathogenic roles have as yet been demonstrated (28). The AAVs rely on another “helper” virus to replicate, usually an AdV, but in their absence AAVs integrate in a site-specific manner into the human genome. The International Committee on Virus Taxonomy defines species within the genus Bocavirus as probably antigenically distinct, with natural infection confined to a single host species. Species are ⬍95% related by nonstructural gene DNA sequence. To date, studies of HBoV have addressed only the molecular criterion. This is indeed the main criterion, since there have been no comparative antigenic studies among any of the species of this genus. Although humans are assumed to be the natural host of HBoV, it should be noted that no studies have investigated lower animals for the presence of HBoV. BIOLOGY OF BOCAVIRUS The members of the family Parvoviridae are small, nonenveloped viruses. They have isometric nucleocapsids with diameters of 18 to 26 nm that contain a single molecule of linear, negative-sense or positive-sense, single-stranded DNA. The complete genome has a length of approximately 4,000 to 6,000 nucleotides (nt) (1, 2). The complete genome length of HBoV has not been determined, but at least 5,299 nt were identified in one of the reference strains. It can be assumed from the genome structure
CLIN. MICROBIOL. REV.
of other parvoviruses that the genomic DNA of bocavirus is flanked by hairpin structures. These structures cannot be deciphered by sequencing methods alone; thus, the complete sequence of the entire genome will not be available until the flanking structures are elucidated (2). The genome contains three proposed open reading frames, with two open reading frames putatively encoding the nonstructural proteins (NS1 and NP-1) and one encoding two viral capsid proteins, VP1 and VP2; the VP2 sequence is nested within VP1 (2). The function of the HBoV NS1 protein is unknown, but one could speculate on its role in HBoV DNA replication, since the related protein in other parvoviruses is likely to be involved in the binding and hydrolysis of nucleoside triphosphates and to have helicase activity (85). NP-1 is absent from other parvoviruses and its function is unknown (2, 65). Phylogenetic analyses have shown that two genetically distinct but very closely related clusters cocirculate in the United States, Sweden, Canada, and France (7, 35). As expected, the deduced coding sequence for the structural proteins VP1 and VP2 from different isolates showed high variability compared to the coding sequences for the nonstructural NS1 and NP-1 proteins, reflecting the more immunogenic character of the virion-associated proteins. The cells hosting HBoV replication have not been determined. Parvoviruses in general require proliferating cells for their replication. Studies of animal bocaviruses suggest infection of respiratory and gut epithelium and lymphatic organs (18, 19). HBoV DNA is present in patients with ARTI and sometimes reaches high copy numbers in respiratory tract secretions, consistent with infection of the respiratory epithelium (1). HBoV DNA has also been detected in the sera of patients with ARTI and in the feces of patients with ARTI and/or gastroenteritis, suggesting the possibility that a range of cells may support HBoV replication in vivo (1, 27, 50, 56, 73). Until recently, HBoV infection could be identified only by the detection of its nucleotide sequence. In a recent report, Brieu et al. described parvovirus-like particles in HBoV DNApositive NPAs by electron microscopy (12). Confirmation of these findings by immunoelectron microscopy with a (hitherto unavailable) HBoV-specific antibody would support the assumption that HBoV DNA, at least at high copy numbers, is virion associated. Antibodies elicited in humans against HBoV structural proteins have also recently been demonstrated (22, 33). LABORATORY DIAGNOSIS To date, the detection of HBoV has been performed predominantly on NPAs and swabs and has been possible only with PCR-based methods, since no virus culture method, animal model of infection, or antibody preparation for antigen detection has been available (2). No comparative studies to identify an optimal sampling site have been reported, and the selection of a sampling site is also hindered by a lack of knowledge about the site of HBoV replication. Specimen handling and storage is infrequently detailed in the published studies. However, the most frequent approach is certainly immediate or batched column-based nucleic acid extraction and PCR testing of convenient populations by use of patient material that has been previously stored after routine microbial testing.
VOL. 21, 2008
Oligonucleotide sequences from PCR methods described to date are summarized in Table 1, but as of yet no comparative studies have identified an optimal gene target or oligonucleotide set(s). For diagnostic purposes, more-conserved genetic regions are preferred; thus, primers directed toward the NS1 gene should yield the most robust assays. However, the limited genetic variability of HBoV allows multiple suitable PCR targets, including the frequently targeted NP1 gene. The use of real-time PCR serves to minimize the risk of amplicon carryover contamination, reduce the result turnaround time, and add an extra layer of specificity (if an oligoprobe-based approach is employed) and can prove less costly overall. Different research groups have described real-time PCR assays that permit some degree of quantification of the viral load in respiratory secretions (1, 37, 45, 62). Since there is no way to standardize respiratory tract specimen collection, respiratory virus quantification by PCR is better described as being semiquantitative (47). Nevertheless, recent results obtained by “quantitative” realtime PCR suggest that high HBoV viral loads (defined as ⬎104 copies/ml) are frequently present as the sole viral finding for children admitted for acute wheezing, while the clinical significance of low to moderate viral loads is uncertain. High viral load in the respiratory tract was frequently associated with the detection of HBoV DNA in the blood (1). HBoV DNAemia declined after the resolution of symptoms, suggesting that high viral load may represent primary infection. Fry et al. (27) compared patients with pneumonia to healthy control subjects. Quantitative results were not reported in detail but, importantly, they found that the healthy controls exclusively had low numbers of HBoV DNA copies in respiratory specimens, while both high and low HBoV DNA loads were found among those cases with pneumonia. Low to moderate viral load is relatively commonplace among studies (62, 38, 45), suggesting that a large proportion of HBoV detection by PCR may represent virus shedding of uncertain clinical relevance. Thus, standardized diagnostic tests that can more accurately identify primary infections, which are more likely the true symptomatic cases, are a top priority for future HBoV research. The predictive value of high virus copy numbers as well as the diagnostic value of PCR testing of blood samples should be further investigated, but if its limitations are kept in mind, quantitative PCR is a useful interim tool for understanding the course of HBoV infection. Preliminary serological studies have recently been published (22, 33) and it is expected that serology will be a very useful diagnostic addition to the study of HBoV infection, as it has been for B19V (83). HBoV AND RESPIRATORY TRACT DISEASE The fact that HBoV is prevalent in samples from patients with ARTI does not guarantee a causative role for the symptoms. For example, many viruses are transmitted via the respiratory tract without triggering substantial respiratory symptoms. Establishing the causative role of a specific agent in disease is a thorough process requiring multiple studies (26). It is particularly difficult to do so in the absence of culture systems and/or animal models, which is a problem common to studies of other newly identified viruses. Nevertheless, the pathogenicity of newly identified HCoV or HRV strains has
HBoV: PASSENGER OR PATHOGEN?
293
not been a major issue of debate, most likely because of their genetic relatedness to other established respiratory pathogens. With HBoV, the situation is different and confounded by several facts. First, HBoV is not related to a known human respiratory pathogen. Second, HBoV may be shed persistently, since other human parvoviruses (B19V, PARV4, and the AAVs) have the capacity for asymptomatic persistence (41, 44, 50). Third, HBoV is commonly detected in association with other respiratory viruses which have an established pathogenic potential. These facts raise the possibility that HBoV detection in respiratory tract samples simply reflects asymptomatic persistence or prolonged viral shedding. Another hypothesis is that HBoV is reactivated or produces a transient asymptomatic superinfection that is triggered by the presence of another replicating respiratory agent. A few studies providing data relevant to these issues have been published (1, 2, 27, 33, 35, 48, 49). The first description of HBoV by Allander et al. (2) did, as mentioned earlier, include a study indicating a statistical association between the detection of HBoV on one hand and the patient suffering from otherwise unexplained ARTI on the other hand. Diagnostics for other viruses was incomplete. However, simple asymptomatic shedding of HBoV would still not result in the observed skewed distribution of HBoV findings. Manning et al. (49) identified HBoV in stored respiratory tract samples and compared the frequencies of reported symptoms associated with each of the different agents sought. Of the 21 HBoV-positive patients, 20 children had symptoms of ARTI versus 1 asymptomatic child, a situation similar to that for RSV but different from what was found for AdVs. The most common clinical diagnosis was “lower RTI,” made for 15 patients (72%). To date, five studies have included control groups of asymptomatic children (1, 27, 35, 48, 49). All studies found highly significant prevalence differences between individuals with ARTI and asymptomatic individuals. Kesebir and coworkers detected HBoV DNA from 22 of 425 NPAs of symptomatic children, while none of the 96 asymptomatic children tested positive for HBoV (35). Allander et al. found no positives among 64 asymptomatic children compared to 49 of 259 (19%) positive samples from children with acute wheezing (1). Unfortunately, in these studies the type of specimen varies between both groups, with an unknown impact on the efficiency of collection, nucleic acid extraction, and PCR sensitivity. In the study of Allander et al., the asymptomatic children were slightly older than the children with ARTI (1). Maggi et al. tested 335 children with ARTI and 51 asymptomatic children (30 healthy infants and 21 preadolescent healthy children) and detected 4.5% positives among the nasal swabs of ARTI cases and no HBoV in nasal swabs of asymptomatic children (48). However, the main weakness of this study is that cases and controls were sampled during different years, which may have falsely lowered the detection of virus in the asymptomatic group. One recently published study by Fry et al. (27), performed in Thailand but coordinated by the Centers for Disease Control and Prevention (Atlanta, GA), included nasopharyngeal swabs from 1,168 patients with community-acquired pneumonia, 512 patients with “influenza-like illness,” and 280 asymptomatic
294
SCHILDGEN ET AL.
CLIN. MICROBIOL. REV.
TABLE 1. Overview of those published protocols describing oligonucleotide sequences used for PCR detection of HBoV Study (reference)
Detection method
Probe sequence and labelinga
Boca-forward (GGAAGAGACACTGGCAGAC AA); Boca-reverse (GGGTGTTCCTGATGA TATGAGC) 188F (GAGCTCTGTAAGTACTATTAC); 542R (CTCTGTGTTGACTGAATACAG) HBoV 01.2 (TATGGCCAAGGCAATCGTCCA AG); HBoV 02.2 (GCCGCGTGAACATGAG AAACAGA) VP1/VP2F (GCAAACCCATCACTCTCAAT GC); VP1/VP2R (GCTCTCTCCTCCCAGTG ACAT) VP/VP2–1017F (GTGACCACCAAGTACTTA GAACTGG); VP/VP2–1020R (GCTCTCTCC TCCCAGTGACAT) BocaRT1 (CGAAGATGAGCTCAGGGAAT); BocaRT2 (GCTGATTGGGTGTTCCTGAT) BocaSEQ1 (AAAATGAACTAGCAGATCTTG ATG); BocaSEQ4 (GAACTTGTAAGCAGA AGCAAAA); BocaSEQ2 (GTCTGGTTTCCT TTGTATAGGAGT); BocaSEQ3 ( GACCCA ACTCCTATACAAAGGAAAC) GGACCACAGTCATCAGACCCACTACCATC GGGCTG Same as that found in the work of Allander et al., 2005 (2)
FAM-CTGCGGCTCCTGCTCCTGTGATTAMRA
NP-1
None
NP-1
None
NP1
None
VP1/2
None
VP1/2
FAM-CACAGGAGCAGGAGCCGCAGTAMRA None
NP1
None
VP1
GGAAGAGACACTGGCAGACAACfluorescein; LC-Red 640-CATCACAGG AGCAGGAGCCG None
NP1
Allander et al., 2007 (1)
Real-time PCR (LightCycler)
Allander et al., 2005 (2) Arden et al., 2006 (5); Sloots et al., 2006 (68) Bastien et al., 2006 (7)
PCR
Bastien et al., 2007 (8)
PCR
Foulonge et al., 2006 (24)
Real-time PCR (LightCycler) Sequencing
Kesebir et al., 2006 (35) Kleines et al., 2007 (37)
PCR
Kupfer et al., 2006 (39); Simon et al., 2007 (66) Lin et al., 2007 (43)
PCR
OS1 (CCCAAGAAACGTCGTCTAAC); OS2 (GTGTTGACTGAATACAGTGT)
Real-time PCR (TaqMan)
Lu et al., 2006 (45)
Real-time PCR (iCycler iQ realtime detection system 关Bio-Rad兴)
Forward primer (AGCTTTTGTTGATTCAAG GCTATAATC); reverse primer (TGTTTCCC GAATTGTTTGTTCA) Primer, fwd (TGCAGACAACGCYTAGTTGT TT); Primer, rev (CTGTCCCGCCCAAGAT ACA) Primer, fwd (AGAGGCTCGGGCTCATAT CA); Primer, rev (AGAGGCTCGGGCTCAT ATCA) Outer sense primer (TATGGGTGTGTTAATC ATTTGAAYA); outer antisense primer (GT AGATATCGTGRTTRGTKGATAT); inner sense primer (AACAAAGGATTTGTWTTY AATGAYTG); inner antisense primer (CCC AAGATACACTTTGCWKGTTCCACCC) Outer primers used were CCAGCAAGTCCTC CAAACTCACCTGC and GGAGCTTCAGG ATTGGAAGCTCTGTG; inner primers followed the sequence of the primer sequences 188F and 542R TAATGACTGCAGACAACGCCTAG; TGTCC CGCCCAAGATACACT BoV2466a (TGGACTCCCTTTTCTTTTGTA GGA) targeting NP1 2466–2443 (real-time PCR); BoV3885s (ACAATGACCTCACAGC TGGCGT) (phylogenetic analysis); BoV4287s (CAGCCAGCACAGGCAGAATT) (phylogenetic analysis); BoV4456a (TCCAAATCCTG CAGCACCTGTG) (phylogenetic analysis); BoV4939a (TGCAGTATGTCTTCTTTCTGG ACG) (phylogenetic analysis) Primer forward (CACTGGCAGACAACTCAT CACA); primer reverse (GATATGAGCCCG AGCCTCTCT) HBoV-UP (AGGAGCAGGAGCCGCAGCC); HBoV-DP (CAGTGCAAGACGATAGGT GGC) NP-1 s1 (TAACTGCTCCAGCAAGTCCTC CA); NP-1 as1 (GGAAGCTCTGTGTTGAC TGAAT); NP-1 as1 and NP-1 s2 (CTCACCT GCGAGCTCTGTAAGTA) VP s1 (GCACTTCTGTATCAGATGCCTT); VP as1 (CGTGGTATGTAGGCGTGTAG); VP s2 (CTTAGAACTGGTGAGAGCACTG)
Manning et al., 2006 (49)
PCR PCR
Real-time PCR (LightCycler)
Nested PCR
Qu et al., 2007 (59) Neske et al., 2007 (56)
Real-time PCR (TaqMan) Real-time PCR (Light Cycler) and phylogenetic analysis
Regamey et al., 2007 (60)
Real-time PCR (TaqMan)
Schenk et al., 2007 (62)
Real-time PCR (LightCycler)
Smuts and Hardie, 2006 (69)
Seminested PCR
a
Target region
Primer name (sequence)
NP1
FAM-TCTAGCCGTTGGTCACGCCCTG TG-TAMRA
NS
FAM-CCAGGATTGGGTGGAACCTGC AAA-Black_Hole_Quencher
NS1
FAM-AGGAACACCCAATCARCCACCT ATCGTCT-Black_Hole_Quencher
2478–2497; 2558–2537
None
NS
None
NP
FAM-TTCCACCCAATCCTGGT-MGB FAM-TGAGCTCAGGGAATATGAAAG ACAAGCATCG-TAMRA
NP1; VP2
AGCAGGAGCCGCAGCCCGA
NS1
HBoV-P: FAM-ATGAGCCCGAGCCTC T-TAMRA
NP1
None
NP1
None
VP1/2
FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine; MGB, minor groove binder (Applied Biosystems).
VOL. 21, 2008
individuals. HBoV DNA was detected in only 3 asymptomatic individuals (1%), whereas 20 out of 512 (3.9%) outpatients with “influenza-like illness” (according to the WHO definition) and 53 (4.5%) out of 1,168 hospitalized patients with the diagnosis “pneumonia” tested positive for HBoV (27). For children aged from 0 to 4 years, the HBoV prevalence was 12% among pneumonia cases and 2% among asymptomatic controls. To date, this is the only study from which all groups have been sampled in the same way, making these data more robust. Among hospitalized children of ⬍5 years of age with the diagnosis “pneumonia,” HBoV was the third most commonly detected virus (12%). Higher prevalence could be confirmed only for RSV and HRV (27). Viral loads of this study were reported separately (45). Most positive samples among all groups had low viral loads but, importantly, high loads were seen only among cases and not among asymptomatic controls. A main concern regarding studies comparing virus prevalences in respiratory tract samples of symptomatic and asymptomatic individuals is the risk for bias related to respiratory tract sampling. An inflammatory process, regardless of cause, will produce a cell-rich mucoid secretion, easily available for sampling, while asymptomatic individuals have very little nasopharyngeal secretion at all. Thus, the detection of, e.g., an intracellular persisting virus could very well be enhanced by an inflammatory process regardless of its cause. The main alternative hypothesis to HBoV being a pathogen is that the virus is persisting or being shed for long periods from the respiratory tract at copy numbers near the lower limit of PCR detection. Because of these possibilities, comparisons of prevalence among symptomatic versus asymptomatic subjects must be interpreted with great care unless viral loads are reported. It is also possible to establish a statistical association between HBoV and disease without using asymptomatic controls. Allander et al. (1) studied patients hospitalized for acute wheezing in Finland and found that the occurrence of HBoV in blood was linked in time with an acute infectious episode and normally disappeared after recovery. In another statistical analysis of the data, HBoV-positive patients with and without other pathogens detected in the respiratory tract were compared. HBoV was significantly more prevalent in patients where no other virus explaining the symptoms was detected. Interestingly, only the cases with high HBoV loads showed this association. Thus, in two ways, internal symptomatic controls could be used to support a statistical association between HBoV and disease in this study. Results were highly significant and at the same time 76% of HBoV-cases were codetections with other viruses, showing that frequent codetections are not necessarily an argument against disease association. The study suggested that high-load and viremic HBoV infection is associated with respiratory tract symptoms, while detection of a low viral load in the nasopharynx alone has uncertain relevance. It was hypothesized that these two entities represent primary infection and persistence, respectively, each accounting for approximately half of the HBoV findings in this particular material. This hypothesis has recently been confirmed by applying serology to the same material (33). Further studies are needed in order to determine the length of possible viral shedding or persistence. Regamey et al. detected HBoV DNA in one patient’s respiratory specimen 3 weeks after the acute phase of infection (60).
HBoV: PASSENGER OR PATHOGEN?
295
In summary, several studies have found a statistical association between HBoV and acute respiratory symptoms, in a way that is consistent with a causal role. However, accurately establishing a causal relationship will require further studies, since current data also indicate that HBoV does not have a causal role for many of the ARTI cases in which it is detected. The diagnostic value in the individual case of detecting HBoV DNA in the respiratory tract therefore remains unclear. Possible Role of Coinfections While the main hypothesis explaining the frequently observed HBoV codetections involves some kind of innocuous persistence or prolonged shedding, a possible role for HBoV as a true copathogen remains uncertain and uninvestigated. Its frequent presence alongside other viruses cannot be questioned (Table 2). The results of our University of Bonn study reported a codetection frequency of 36%. Such high percentages have been reported by most studies which have looked for coinfections, with codetection frequencies of 18% to 90% being reported (2, 27). Manning and coworkers detected one or more additional viruses in 43% (23/53) of HBoV-positive samples (49). The overall frequency of codetection among HBoVnegative samples that were positive for other viral pathogens in the same study was 17% (47/271) (P ⬍ 0.001). One explanation for the wide range of results is the nonstandardized diagnostic panel common to published studies. In addition, differences in test sensitivity have to be considered, in particular in light of the high proportion of low-load infections (14, 77). Codetection of another virus with HBoV, usually when the latter is at low viral load, occurs frequently from patients with ARTI, but HBoV is still rare in asymptomatic individuals. One hypothesis for this is that detection of innocuous HBoV shedding is enhanced by airway inflammation caused by another virus, as discussed above. Another is that HBoV is involved in the pathogenesis and, in some way, the aggravation of symptoms, so that it is frequently observed in hospitalized patients. Yet another possibility is that HBoV is a helper virus which aids other viruses or itself requires the aid of another ongoing infection for activation or reactivation of replication. There are currently no data defining a mechanism by which HBoV could be described as either a pathogen or a passenger. To date, it remains uncertain whether codetection with any respiratory viruses results in more-serious clinical outcomes. This is not a question unique to HBoV infections but an important facet of ARTIs in general that must be addressed in the future, perhaps with the aid of animal models. EPIDEMIOLOGY Reports suggest that HBoV has worldwide endemicity. It has been detected over several years in many countries, including Sweden, Australia, the United States, Japan, Germany, South Africa, Jordan, France, Canada, Iran, Spain, The Netherlands, Korea, Thailand, Switzerland, and China (1, 2, 4–7, 14, 15, 24, 25, 27, 34–37, 39, 43, 45, 46, 48–50, 52, 54, 55, 59, 60, 62, 66, 68, 69, 73, 74, 77). Based on phylogenetic analysis of predicted amino acid alignments, HBoV exists worldwide as a single lineage composed of two subtly different genotypes, as shown in Fig. 1. The
1,474 1,209
San Diego, CA
Saskatchewan, Canada
324 341
Queensland, Australia
Cape Town, South Africa 527 (stool)
252 112
Beijing, China Berne, Switzerland
San Sebastia´n, Spain
261
257 children with fever
Rotterdam, The Netherlands Rasht, Guilan, Iran
48 (9.1)
38 (11.0)
18 (5.6)
5 (5.5) 5 (4.2)
21 (8.3)
(4)
18 (5.7) A, 9 (4.5); B, no HboV detected; C, no HboV detected 4 (1.6)
7 (2.7)
22 (5.2)
12 (12.8)
57 (18.3)
53 (4.5)
27 (8); 17/225 (7.5) of the “virus negative” 26 (4.4)
58 (11.3)
18 (1.5)
82 (5.6)
49 (19)
17 (3.1)
No. (%) of HBoVpositive samples
⬍36 mo
—
⬍36 mo
0 —
—
—
0
NA
9 (3.4–11.3) NA
13 ⫾ 2
1.0–2.3 yr
0
1.0–2.3 yrc c
89 100%
—
75
—
—
—
15.0 (9–31) A, 16 ⫾ 13
“Infants and children”
12.5 (1–24)
7.8 (1–30)
8.0
NA (1 mo–ⱖ65 yr)
NA
NA
0 0
5 (24) asthma
0
0
NA 1 (11) neurological
NA
12 (60)
5/12 (41)
NA
NA
16 (62)
NA
—
14 (1–69); 15 (1–83) of the “virus negative” 13.0 (4–43) —
†e
21 (31; 19% prematurity) NA
NA
9 (64)
No. (%) of patients with relevant comorbiditiesg
—
50
57
—
—d
% Hospitalized
NA
138.0 (9 mo–60 yr)
HBoV pos only, 13.5 (8–48) HBoV pos only (n ⫽ 12), 15.6 (9.6–38.4) 12.0 (10 days to 16 yr)
Median age (range) (mo)b
*
37
56
10 56
33
33
HCoV 229E RSV, AdV, rhinovirus (2⫻), HCoV NL63 RSV (2/38; 5%); AdV (1/18; 6%); HMPV (1/18; 6%) RSV (14/40; 35%); rhinovirus (4/ 40;10%); influenza virus (5/40; 13%); HCoV (3/40;8%); AdV (1/40; 3%) 40 HBoV-positive respiratory samples: 25 (62.5%) coinfections with other viruses (13 RSV, 3 rhinovirus, 3 influenza virus A, 2 HCoVOC43, 1 AdV, 1 influenza virus B); 48 HBoV-positive fecal samples: 28 (58.3%) coinfections with another intestinal pathogenj
Rhinovirus, RSV, parainfluenza virus, AdV Rhinovirus, RSV, parainfluenza virus, AdV RSV, AdV, or influenza virus A
‡ RSV (3/9; 33%); rhinovirus, influenza virus A, HMPV (1/9; 11%) 43
NA ‡h 44
*
RSV (5/26; 19%); AdV (2/26; 8%); HMPV (2/26; 8%) RSV (23%); human parainfluenza virus (23%); AdV (2%); influenza virus A/B (9%); rhinovirus (42%) AdV (25/57; 44%); RSV (23/57; 40%); HMPV (1/57; 2%), influenza virus A (1/57; 2%) RSV (42%)
NA
5*
42
72
83
35
37
38
AdV (7/58; 12%); RSV (5/58; 9%); HMPV (5/58; 9%); Parainfluenza viurs 3 (3/58; 5%) RSV (5/27;19%); HMPV (4/27; 15%); AdV (1/27;4%)
*f
12
Rhinovirus, enterovirus (43%); AdV (16%); RSV (14%) RSV (9/82; 11%)
RSV (2/17; 12%); AdV (1/17; 6%)
Other viral copathogens (no.; %)
76
18
Patients with coinfection (%)
SCHILDGEN ET AL.
Vicente et al., 2007 (73)
Manning et al., 2006 (49) Monteny et al., 2007 (54) Naghipour et al., 2007 (55) Qu 2007 et al., (59) Regamey et al., 2006 (60) Sloots et al., 2006 (68) Smuts and Hardie, 2006 (69)
Edinburgh, Scotland
257
Zhejiang Province, China Sapporo, Japan Pisa, Italy 318 Total of 335: A (infants), n ⫽ 200; B (adults), n ⫽ 84; C (asmptom. children), n ⫽ 51 924i
425
New Haven, CT
Ma et al., 2006 (46) Maggi et al., 2007 (48)
94
Aachen, Germany
Kleines et al., 2007 (37) Kesebir et al., 2006 (35) Lin et al., 2007 (43)
312
Amman, Jordan
792
Nonthaburi, Thailand
Kaplan et al., 2006 (34)
589
Montpellier, France
Foulongne et al., 2006 (24) Fry et al., 2007 (27)
336 (225 “virus negative”; 111 “virus positive”)
Seoul, South Korea
515
259
Turku, Finland
Seoul, South Korea
540
No. of NPAs testeda
Stockholm, Sweden
Study region
Chung et al., 2006 (15)
Allander et al., 2005 (2) Allander et al., 2007 (1) Arnold et al., 2006 (6) Bastien et al., 2006 (7) Choi et al., 2006 (14)
Study (reference)
TABLE 2. Basic data from 23 analyzed studies 296 CLIN. MICROBIOL. REV.
VOL. 21, 2008
HBoV: PASSENGER OR PATHOGEN?
greatest variability was observed within the 285-bp portion of VP1/VP2 (Fig. 1C), whereas significantly lower genetic variability was seen for viral sequences within the NS1 and the NP-1 genes (Fig. 1A and B).
b
asmptom., asymptomatic. pos, positive; NA, data not available. c This study included children with fever from 3 months to 6 years of age. d –, this study included NPA samples from hospitalized patients. e †, this study included patients without predisposing risk factors, such as an underlying disease. f *, this study included NPA samples that had tested negative for influenza virus A/B, parainfluenza virus 1/2/3, AdV, and RSV. g Relevant comorbidities are those underlying diseases or conditions that may have, or are known to have, any influence on the clinical severity of a viral respiratory infection. h ‡, this study included NPA samples that had tested negative for influenza virus A/B, RSV, and HMPV. i Study included 924 NPA samples from 574 individuals. j Salmonella enterica serovar Enteritidis (n ⫽ 1), Campylobacter jejuni (n ⫽ 5), rotavirus (n ⫽ 14), norovirus (n ⫽ 7), C. jejuni and norovirus (n ⫽ 1).
Prevalence of HBoV
a
87 (10.3) Wu ¨rzburg, Germany
835
22 (18 days to 8 yr)
—
NA
39
RSV (3/11; 27%); norovirus (1/11; 9%) RSV (14/87; 16%); influenza virus A (9/87; 10%); AdV (9/87; 10%); parainfluenza virus 1/2/3 (1/87; 1%); influenza virus B (1/ 87; 1%) 36 NA — 9 (3 mo to 17 mo) 11 (2.8) 389 Bonn, Germany
Vo ¨lz et al., 2007 (74) Weissbrich et al., 2006 (77)
297
The proportion of respiratory specimens from symptomatic hospitalized children that contain HBoV sequences has ranged from 1.5% to 19% (1, 7) Most children infected with HBoV have been younger than 24 months (2, 15, 55, 59, 68, 69), but older children may also be affected (7, 14). For example, 4 of 27 (15%) positive specimens in the study of Chung et al. were obtained from children of ⬎36 months of age (15). Thus, it seems reasonable to include older children into prospective surveillance studies. As expected, studies which included only hospitalized children and children with wheezing (14) presented a higher illness severity than those studies that analyzed respiratory specimens from outpatients as well (6, 59, 60). In order to determine a more realistic prevalence of HBoV in respiratory tract samples, future prospective studies should also include appropriately age-matched children and adults embodying a clinical description of “asymptomatic” as well as patients presenting with mild illness. There are few systematic studies including adults, but available studies indicate a very low virus prevalence by PCR in the respiratory tract of adults (2, 7, 27, 49). Recently, seroepidemiological data were published from Japan by Endo et al. (22). Anti-HBoV antibodies were detected in 145 of 204 (71.1%) serum samples from people aged from 0 month to 41 years from the Hokkaido Prefecture. The seroprevalence was lowest (5.6%) in the age group from 6 to 8 months and highest in the age groups older than 6 years (94.1 to 100%). The findings of high antibody prevalence and low virus prevalence among individuals older than 6 years are consistent with each other and suggest that there may be protective immunity after past infection. Positive antibody titers were also detected in the age group younger than 6 months, but this phenomenon is explained by the antibody transfer via the placenta to the fetus predominantly in the third trimester of pregnancy (22). Seasonal Distribution of HBoV Detection According to the literature, HBoV DNA-positive ARTIs occur in children across a range of months. The peak “respiratory season” varies from year to year (79). Therefore, it is not feasible to draw conclusions concerning the epidemiology of a newly identified virus based on snapshot analyses of single seasons or even multiple respiratory seasons. In accordance with the University of Bonn’s data, most authors reporting from regions with temperate climates have observed a higher occurrence of HBoV detections during the winter and spring months (2, 69). Choi et al. (Korea 2000 to 2005) reported a relatively high occurrence of HBoV in the late spring and early summer. They did not reveal any obvious correlation to changes in the parallel RSV season (14). Maggi et al. from Italy could not confirm a seasonal distribution of the HBoV infections in their study of hospitalized infants with RTI (48), but they found significant differences between years, with no
298
SCHILDGEN ET AL.
CLIN. MICROBIOL. REV.
FIG. 1. Phylogenetic analysis of HBoV. Phylogenetic trees are based on 61 partial NS1 genes (245 nt, corresponding to nt positions 1509 to 1753 in the ST1 isolate [accession number DQ000495]) (A), 167 partial NP-1 genes (242 nt, corresponding to nt positions 2340 to 2581 in the ST1 isolate) (B), and 133 partial VP1/VP2 genes (285 nt, corresponding to nt positions 4547 to 4831 in the ST1 isolate) (C). Sequences were aligned using the program CLUSTAL_X, version 1.83 (71). Phylogenetic relationships of the aligned sequences were inferred from the generated alignment by the neighbor-joining method (61). The reliability of the tree topology was evaluated by 500 replicates of bootstrap resampling (84). Phylogenetic trees were visualized using the TREEVIEW software tool (58). Trees show the HBoV sequences used for the analysis and their individual geographical origins. The numbers in parentheses indicate the numbers of isolates for the respective locations. For reasons of clarity, this figure does not include GenBank accession numbers. Detailed information on GenBank accession numbers of sequences used for the phylogenetic analysis is available upon request. (D) Phylogenetic placement of HBoV and other members of the genus Parvovirinae. Bootstrapped (n ⫽ 1,000) neighbor-joining tree based on 80% of the complete genomic nucleotide sequence. Bootstrap values (%) are indicated at each branching point. B19, erythrovirus B19; PTMPV, pig-tailed macaque parvovirus; RMPV, rhesus macaque parvovirus; SPV, simian parvovirus; ChPV, chipmunk parvovirus; BPV2 and BPV3, bovine parvovirus 2 and 3; GPV, goose parvovirus; MDPV, Muscovy duck parvovirus; AMDV, Aleutian mink disease virus; PPV, porcine parvovirus; CPV, canine parvovirus; RPV-1a, rat parvovirus-1a; KRPV, Kilham rat parvovirus; MPV1, mouse parvovirus 1; MVM, minute virus of mice; MVC, minute virus of canines.
HBoV detected in any specimen from 2000 to 2002 (n ⫽ 43, including 30 specimens from symptomatic infants). The weakness of most retrospective studies is that more specimens are collected during the winter months, because that is the epidemic season for most viral RTIs. Both more-active sampling and enhanced detection of HBoV by other infections, as discussed above, could therefore lead to false observations of seasonal patterns. It must also be kept in mind that the numbers reported in most studies probably reflect a mix of incidence and carrier prevalence. The true incidence and seasonality of primary HBoV infection remain unknown.
Transmission Nothing is known about the routes of HBoV transmission. Because of its sometimes very high copy numbers in respiratory tract secretions, aerosol and contact transmission are likely effective, as they are for other respiratory viruses. Hand-to-hand, hand-to-surface, and self-inoculation routes have certainly proven to be efficient steps in the transmission of the “common cold.” Since we know that HBoV DNA exists in some capacity within feces, the possibility of fecaloral transmission must also be considered. Further studies should include more testing of stool samples for HBoV to
VOL. 21, 2008
HBoV: PASSENGER OR PATHOGEN?
299
FIG. 1—Continued.
confirm the extent and nature of virus DNA shedding and the capacity of the virus to survive disinfectants (10, 11, 17, 31, 38) and permit broader investigations of a possible role for HBoV as an enteric pathogen. So far there have been no studies on the tenacity of the virus or about the effect of commonly used hospital-grade disinfectants. Since other parvoviruses are known to be highly resistant to disinfectants (10, 11), such investigations will be important but will require an HBoV culture system or animal model of infection. Kesebir and coworkers reported 3 infants (14%) of 22 with presumed nosocomial HBoV infection (35). The infected infants were 1, 4, and 6 months of age at the time their NPAs were sampled and had been hospitalized since birth. Two of the three patients had HBoV-positive NPAs within a period of 4 days and had been cared for by the same medical personnel on the same ward. Phylogenetic analysis of the two positives showed identical nucleotide sequences in both the NP1 and VP1/VP2 gene region; however, be-
cause of the low genetic variability of HBoV, the significance of such a finding should not be exaggerated. Notably, vertical transmission could not be excluded. Three of 12 HBoV-positive children reported in the study of Kleines et al. developed symptoms of ARTI after at least 4 weeks of hospitalization (37). Since the incubation period of HBoV infection is unknown, it is not possible to state that this was nosocomial transmission. The presence of HBoV DNA in the blood combined with suspected persistence could have implications for transfusion medicine, since organs or blood products derived from acutely infected donors could be contaminated and serve as a source of infection (1, 59). However, unlike PARV4, HBoV was not detected in plasma pools (28). CLINICAL OBSERVATIONS While the role for HBoV in causing any symptoms remains unclear, studies of the symptoms reported for HBoV-positive
300
SCHILDGEN ET AL.
CLIN. MICROBIOL. REV. TABLE 3. Diagnosis at discharge from hospital (%) % Patients from indicated study with indicated diagnosis upon dischargea:
Study (reference)
Allander et al., 2005 (2) Allander et al., 2007 (1) Arnold et al., 2006 (6) Bastien et al., 2006 (7) Choi et al., 2006 (14) Chung et al., 2006 (15) Foulongne et al., 2006 (24) Kaplan et al., 2006 (34) Kesebir et al., 2006 (35) Ma et al., 2006 (46) Maggi et al., 2007 (48) Manning et al., 2006 (49) Naghipour et al., 2007 (55) Qu et al., 2007 (59) Vo ¨lz et al., 2007 (74) Weissbrich et al., 2006 (77)
Upper RTI
Croup
Bronchitis
Bronchiolitis
Pneumonia
Asthma exacerbation
Gastrointestinal symptoms
Febrile seizures
NA 0b 24 22 5 24 15 NA NA —c 0 29 0 0 9 40
NA 0 4 NA 8 0 NA NA NA NA 0 NA 0 0 9 NA
NA 25 NA NA NA 76 NA NA NA 44 0 NA 14 29 45 16
NA 67 26 11 25 0 46 NA NA 11 55 NA NA NA 3 3
NA 75 24 17 56 0 11 NA NA 33 45 NA 46 62 64 17
NA 8 24 NA 11 0 27 NA NA 5 0 NA 10 NA NA NA
NA 0 16 NA NA 12 NA NA 25 NA 11 NA NA 9 9 NA
NA 0 NA NA NA NA NA NA NA NA 0 NA NA 5d 9 9
a
Data are percentages for all investigated patients unless otherwise indicated. NA, data not available. Allander et al. (1) reported the diagnosis of acute otitis media for 42% of HBoV-positive children with bronchial obstruction without viral coinfection. Study included only patients with lower RTIs. d Qu et al. reported one patient (10 months of age) with an acute life-threatening event. b c
patients nevertheless provide an important starting point. Besides some case reports (39, 62, 66), 23 research study publications were included in this review that contained data about symptoms and outcomes for and radiological findings and laboratory results from HBoV-positive hospitalized children (Tables 2 and 3) (1, 2, 6, 7, 14, 15, 24, 25, 27, 34, 35, 37, 43, 46, 49, 54, 55, 59, 60, 68, 69, 73, 77). We also added our data, which were collected in the winter of 2005/2006 (74). Limitations of Available Studies Only a few studies of HBoV have collected clinical data prospectively (the University of Bonn study presented here [Germany] and the studies of Regamey et al. [Switzerland] [60], Monteny et al. [The Netherlands] [54], Allander et al. [Finland] [1], and Fry et al. [Thailand] [27]). In the remaining studies we cite, laboratory, clinical, and radiological findings have been acquired retrospectively, similar to many studies of human metapneumovirus (HMPV) infection (78, 81). Only nonstandardized, research-only, in-house PCR diagnostics have been employed to date. Because of the obligate use of PCR, one cannot truly talk about “infection”; rather, each HBoV DNA-positive specimen should be described as a virus “detection.” Considering that prolonged shedding of HBoV or reactivation by other infections may account for a remarkable number of the HBoV detections discussed above, it is a severe limitation that diagnostic assays separating these cases from primary infections are not yet available. Most published studies have not taken this into consideration. A lack of international consensus about the definition of certain respiratory diseases is another obstacle to accurately characterizing the clinical outcomes of HBoV infection, just as it is for any respiratory infection. There is no agreement about the definition of obstructive bronchitis, recurrent obstructive bronchitis in infants, bronchiolitis, bronchopneumonia, or lo-
bar pneumonia (3, 70). Six out of the 23 analyzed studies used the diagnosis “bronchiolitis” (6, 7, 14, 24, 25, 46, 77). The percentages of “bronchiolitis” within the diagnostic spectrum ranged from 3.2% to 46% (24, 77). Two studies provided differing definitions (6, 14), whereas the remaining publications did not even comment on the clinical criteria. Only 7 of 23 studies (1, 2, 6, 27, 35, 37, 46) definitively stipulated a radiological confirmation of the clinical diagnosis “pneumonia.” Most studies did not make a distinction between (central) bronchopneumonia and segmental or lobar pneumonia. Symptoms Presumably Associated with HBoV Infection Clinical symptoms most frequently reported in individuals where HBoV is the only detected virus include cough, rhinorrhea, and fever, which are also the most common nonspecific symptoms leading to respiratory viral testing in children. The most common clinical diagnoses given to HBoV-positive patients, with or without coinfections, include upper RTI, bronchitis, bronchiolitis, pneumonia, and acute exacerbation of asthma. This clinical spectrum is in accordance with other viral ARTIs, similar to the situation with RSV infections (75) and with HMPV infections (78, 80). There are no described distinct clinical signs differentiating HBoV-positive infections from those ascribed to other viruses (2, 37). This could imply that HBoV indeed has a clinical picture similar to those seen for other ARTIs or simply that because of the mentioned diagnostic problems with HBoV many of the studied patients were actually suffering from other infections. Symptoms seem to persist for 1 to 2 weeks on average (range, 2 days to 3 weeks) (1, 60); Monteny et al. reported a prolonged course of fever (⬎7 days or recurring) in HBoV-infected patients (54). HBoV has also been detected in individuals with skin rash, although no causal association has been identified (6, 15, 54). Allander at al. reported a 42% incidence of acute otitis media in solely
VOL. 21, 2008
HBoV: PASSENGER OR PATHOGEN?
HBoV-positive patients (2). Except for this report, there are few data on bacterial coinfections. The possibility that HBoV, like the closely related bovine and canine bocaviruses (18, 19), could cause gastroenteritis was raised in the first report on HBoV (2). Gastrointestinal symptoms have been described for up to 25% of all patients (6, 35, 54). Maggi et al. (48) detected HBoV DNA in stools of a 6-month-old boy followed for neurological problems who had presented with diarrhea and bronchopneumonia. Both respiratory and stool specimens were positive for HBoV and antigen negative for rotaviruses, AdVs, astroviruses, and calicivirus 1 and 2. Vicente at al. investigated the presence of HBoV DNA in 527 stool samples from ambulatory patients with gastroenteritis (⬍36 months of age) with or without additional respiratory symptoms (73). Of these, 48 (9.1%) were positive for HBoV DNA. Other enteric pathogens were found in 58% of all HBoV-positive fecal samples (Table 2). In contrast, Lee et al. detected HBoV DNA in only 0.8% of 942 hospitalized children with gastroenteritis (40). Neske and coworkers reported a high frequency of HBoV DNA in stool samples derived from children who were also positive for HBoV DNA in NPAs (56). Chest Radiography Findings In the University of Bonn study, the majority of HBoVpositive patients (10/11) showed symptoms severe enough for physicians dealing with the patients to perform a chest radiograph, and 8 of 10 (80%) patients with a chest radiograph had visible abnormalities (74). In these 11 patients no coinfections were observed. This high percentage of pathology is in accordance with the results of other clinical research groups, which found similar pathology in 43% to 83% of cases (2, 24, 25). The most common diagnosis in this study was (central) bronchopneumonia; in 18% a segmental/lobar pneumonia was diagnosed (74). Cases of HBoV-positive central pneumonia as well as interstitial and lobar pneumonia, especially in newborns and infants, have been described. HBoV and Acute Wheezing ARTIs have frequently been detected in infants with recurrent airway obstruction (“wheezing”) and in older children and adults with asthma exacerbations (32, 63, 64, 80). In fact, the highest frequency of laboratory confirmations are described by studies of children with acute expiratory wheezing, usually attributed to viruses. Recently published clinical studies report asthma exacerbation as a clinical entity in up to 27% of HBoVpositive patients (6, 24, 25), but several of the analyzed studies did not explicitly exclude relevant viral pathogens such as RSV and the HRVs. Half of the patients in the original study by Allander and coworkers presented with asthma as an underlying disease (2). Allander et al. subsequently reported that 49 of 259 (19%) children hospitalized for acute wheezing in Finland were HBoV positive and speculated that this unusually high percentage could imply that wheezing is the main manifestation of HBoV infection. Fry et al. (27) found a statistical association between HBoV detection and reporting wheezing among patients with pneumonia in Thailand. Naghipour et al.
301
found that 5 HBoV-infected patients (24%) had a history of asthma (55), while Maggi investigated respiratory specimens from 22 adult patients with acute asthma exacerbation and did not detect HBoV (48). Chung et al. investigated nasopharyngeal specimens from 231 children (1 month to 5 years of age) hospitalized with acute wheezing (16). Besides RSV (13.8%), HBoV was the most frequently detected virus (13.8%) in 5.6% without coinfection; HMPV and HCoV-NL63 were detected in 7.8% and 1.3% of wheezing children, respectively.
HBoV in Immunocompromised Patients Several clinical research groups have reported HBoV-positive immunosuppressed/immunodeficient patients (6, 49, 69). Arnold and coworkers described two pediatric patients positive for HBoV after organ transplantation (6). Smuts and coworkers reported HBoV detections for eight human immunodeficiency virus-infected pediatric patients (69), and Manning and coworkers described two HBoV-positive immunosuppressed adult patients (49). Kupfer et al. have recently published the clinical case of a severe infection in a 28-year-old HBoVpositive female patient with malignant B-cell lymphoma (39). On admission, the patient had a pancytopenia, high fever, and clinical and radiological signs of pneumonia (reticulonodular infiltrates in the computed tomography scan of the thorax). Despite the application of antibiotics, antifungals, and the antiviral ganciclovir, fever continued for 14 days. HBoV DNA was detected retrospectively, suggesting HBoV as the sole potential pathogen in NPAs. Since unexplained pulmonary disease is common in this group of patients, the role of HBoV in causing the symptoms is unclear. However, in studies to date, most symptomatic adults positive for HBoV DNA have fallen into a category of immunosuppression. On the other hand, this may be the result of a selection bias, since these are the adult or elderly patients in which respiratory diagnostic specimens are taken in case of an infection. HBoV has not been identified in lymphoid tissue and in bone marrow and brain, respectively, from human immunodeficiency virus type 1-infected and uninfected adults upon autopsy (50).
Laboratory Results for HBoV-Infected Patients Very few investigators have been able to document the course of markers of inflammation such as C-reactive protein (CRP) or white blood cell (WBC) count for HBoV-positive patients. None of the first 11 HBoV-positive children treated in our center (University of Bonn) in 2005/2006 fulfilled the laboratory criteria of a suspected bacterial coinfection (WBC, ⬎15 ⫻ 109/liter; CRP, ⬎40 mg/liter) (67). The median WBC count was 11.3 ⫻ 109/liter (range, 6.7 ⫻ 109 to 16.7 ⫻ 109) and the median CRP concentration was 12.5 mg/liter (range, ⬍0.03 to 114) (74). Others reported median WBC and CRP concentrations of similar magnitudes (46). In Allander’s recent report on 12 children with HBoV infection (no viral coinfection) (1), 9 displayed a radiologically confirmed pneumonia. The median WBC was 9.1 (6.3 to 16.3) ⫻ 109/liter and the median CRP was 18 (0 to 78) mg/liter.
302
SCHILDGEN ET AL.
TREATMENT AND PREVENTION The clinical impact of HBoV infection is uncertain, and to date there have been no studies on the benefits of particular therapeutic approaches for HBoV-infected individuals and no proposals for novel therapeutics. Prospective controlled studies evaluating specific treatment approaches for patients infected by HBoV will require analytically sensitive, specific, and clinically relevant diagnostic procedures. In our center (University of Bonn), the high frequency of radiographically confirmed pneumonia (70%) might explain the use of antimicrobial chemotherapy for 82% of HBoV-positive patients. A rapid HBoV testing method capable of identifying clinically relevant cases could reduce the unjustified and generally ineffective use of antibiotics in these patients. If HBoV turns out to contribute significantly to the disease burden on children, possibilities for vaccine development will likely be investigated, like it has been for RSV, HMPV, and parainfluenza viruses. To date, no such studies have been reported. CONCLUSIONS AND FURTHER RESEARCH Our current knowledge of HBoV infection suggests that the virus is sometimes a passenger and sometimes a pathogen in acute respiratory tract disease. A better understanding of the natural course of HBoV infection and an expanded arsenal of diagnostic tests capable of discriminating carriage from infection will be necessary before any clinical questions can be comprehensively addressed. Detection of HBoV DNA in blood and serological assays have shown promising preliminary results. To date, retrospective studies report a peak of HBoV detections during the first and second years of life. Some case reports have raised concerns about serious clinical outcomes among immunosuppressed individuals. To date there is neither a method for virus culture nor an animal model of infection, but hopefully the introduction of serological detection of specific antibodies will permit us some insight into the pathogenesis and natural course of HBoV infection. Many additional questions cannot yet be answered by the studies that have been reported and should be addressed by future studies. How is HBoV transmitted, and is HBoV a causative agent of gastrointestinal diseases? Does the virus persist in the human host? Could coinfection with HBoV increase the severity of concurrent viral infections? What is the immune response to HBoV infection? Can HBoV cause exacerbations of asthma and chronic obstructive pulmonary disease? HBoV might be one of the most recently identified respiratory viruses, but its nature has attracted as much interest and raised as many questions as many of its better-characterized relatives. After decades of research, the most widespread and frequent causes of human infections, the respiratory viruses, are still as confounding as ever.
ACKNOWLEDGMENTS This work was partially supported by grants from the Else-Kro ¨nerFresenius-Stiftung (grant number A 01/05//F 00) and the European Commission (contract number LSHM-CT-2006-037276).
CLIN. MICROBIOL. REV. REFERENCES 1. Allander, T., T. Jartti, S. Gupta, H. G. Niesters, P. Lehtinen, R. Osterback, T. Vuorinen, M. Waris, A. Bjerkner, A. Tiveljung-Lindell, B. G. van den Hoogen, T. Hyypia, and O. Ruuskanen. 2007. Human bocavirus and acute wheezing in children. Clin. Infect. Dis. 44:904–910. 2. Allander, T., M. T. Tammi, M. Eriksson, A. Bjerkner, A. Tiveljung-Lindell, and B. Andersson. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA 102:12891– 12896. 3. American Academy of Pediatrics. 2006. Diagnosis and management of bronchiolitis. Pediatrics 118:1774–1793. 4. Anderson, L. J. 2007. Human bocavirus: a new viral pathogen. Clin. Infect. Dis. 44:911–912. 5. Arden, K. E., P. McErlean, M. D. Nissen, T. P. Sloots, and I. M. Mackay. 2006. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. J. Med. Virol. 78:1232–1240. 6. Arnold, J. C., K. K. Singh, S. A. Spector, and M. H. Sawyer. 2006. Human bocavirus: prevalence and clinical spectrum at a children’s hospital. Clin. Infect. Dis. 43:283–288. 7. Bastien, N., K. Brandt, K. Dust, D. Ward, and Y. Li. 2006. Human bocavirus infection, Canada. Emerg. Infect. Dis. 12:848–850. 8. Bastien, N., N. Chui, J. L. Robinson, B. E. Lee, K. Dust, L. Hart, and Y. Li. 2007. Detection of human bocavirus in Canadian children in a 1-year study. J. Clin. Microbiol. 45:610–613. 9. Binn, L. N., E. C. Lazar, G. A. Eddy, and M. Kajima. 1970. Recovery and characterization of a minute virus of canines. Infect. Immun. 1:503–508. 10. Bonvicini, F., G. Gallinella, G. A. Gentilomi, S. Ambretti, M. Musiani, and M. Zerbini. 2006. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination. Clin. Lab. 52:263–268. 11. Brauniger, S., J. Peters, U. Borchers, and M. Kao. 2000. Further studies on thermal resistance of bovine parvovirus against moist and dry heat. Int. J. Hyg. Environ. Health 203:71–75. 12. Brieu, N., B. Gay, M. Segondy, and V. Foulongne. 2007. Electron microscopy observation of human bocavirus (HBoV) in nasopharyngeal samples from HBoV-infected children. J. Clin. Microbiol. 45:3419–3420. 13. Chen, K. C., B. C. Shull, E. A. Moses, M. Lederman, E. R. Stout, and R. C. Bates. 1986. Complete nucleotide sequence and genome organization of bovine parvovirus. J. Virol. 60:1085–1097. 14. Choi, E. H., H. J. Lee, S. J. Kim, B. W. Eun, N. H. Kim, J. A. Lee, J. H. Lee, E. K. Song, S. H. Kim, J. Y. Park, and J. Y. Sung. 2006. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin. Infect. Dis. 43:585–592. 15. Chung, J. Y., T. H. Han, C. K. Kim, and S. W. Kim. 2006. Bocavirus infection in hospitalized children, South Korea. Emerg. Infect. Dis. 12:1254–1256. 16. Chung, J. Y., T. H. Han, S. W. Kim, C. K. Kim, and E. S. Hwang. 2007. Detection of viruses identified recently in children with acute wheezing. J. Med. Virol. 79:1238–1243. 17. Dowell, S. F., T. J. Torok, J. A. Thorp, J. Hedrick, D. D. Erdman, S. R. Zaki, C. J. Hinkle, W. L. Bayer, and L. J. Anderson. 1995. Parvovirus B19 infection in hospital workers: community or hospital acquisition? J. Infect. Dis. 172: 1076–1079. 18. Durham, P. J., R. H. Johnson, H. Isles, R. J. Parker, R. G. Holroyd, and I. Goodchild. 1985. Epidemiological studies of parvovirus infections in calves on endemically infected properties. Res. Vet. Sci. 38:234–240. 19. Durham, P. J., A. Lax, and R. H. Johnson. 1985. Pathological and virological studies of experimental parvoviral enteritis in calves. Res. Vet. Sci. 38:209– 219. 20. Eis-Hubinger, A. M., D. Dieck, R. Schild, M. Hansmann, and K. E. Schneweis. 1998. Parvovirus B19 infection in pregnancy. Intervirology 41:178–184. 21. El-Mahallawy, H. A., T. Mansour, S. E. El-Din, M. Hafez, and S. Abd-elLatif. 2004. Parvovirus B19 infection as a cause of anemia in pediatric acute lymphoblastic leukemia patients during maintenance chemotherapy. J. Pediatr. Hematol. Oncol. 26:403–406. 22. Endo, R., N. Ishiguro, H. Kikuta, S. Teramoto, R. Shirkoohi, X. Ma, T. Ebihara, H. Ishiko, and T. Ariga. 2007. Seroepidemiology of human bocavirus in Hokkaido prefecture, Japan. J. Clin. Microbiol. 45:3218–3223. 23. Fattet, S., P. Cassinotti, and M. B. Popovic. 2004. Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphocytic leukemia. J. Pediatr. Hematol. Oncol. 26:497–503. 24. Foulongne, V., Y. Olejnik, V. Perez, S. Elaerts, M. Rodiere, and M. Segondy. 2006. Human bocavirus in French children. Emerg. Infect. Dis. 12:1251– 1253. 25. Foulongne, V., M. Rodiere, and M. Segondy. 2006. Human bocavirus in children. Emerg. Infect. Dis. 12:862–863. 26. Fredericks, D. N., and D. A. Relman. 1996. Sequence-based identification of microbial pathogens: a reconsideration of Koch’s postulates. Clin. Microbiol. Rev. 9:18–33. 27. Fry, A. M., X. Lu, M. Chittaganpitch, T. Peret, J. Fischer, S. F. Dowell, L. J. Anderson, D. Erdman, and S. J. Olsen. 2007. Human bocavirus: a novel
VOL. 21, 2008
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47. 48.
49.
50.
51.
parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J. Infect. Dis. 195:1038–1045. Fryer, J. F., E. Delwart, F. M. Hecht, F. Bernardin, M. S. Jones, N. Shah, and S. A. Baylis. 2007. Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion 47:1054–1061. Gaynor, A. M., M. D. Nissen, D. M. Whiley, I. M. Mackay, S. B. Lambert, G. Wu, D. C. Brennan, G. A. Storch, T. P. Sloots, and D. Wang. 2007. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog. 3:e64. Hayes-Lattin, B., T. J. Seipel, K. Gatter, M. C. Heinrich, and R. T. Maziarz. 2004. Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. Am. J. Hematol. 75:142– 145. Hota, B. 2004. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin. Infect. Dis. 39:1182– 1189. Jartti, T., P. Lehtinen, T. Vuorinen, R. Osterback, B. van den Hoogen, A. D. Osterhaus, and O. Ruuskanen. 2004. Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg. Infect. Dis. 10:1095–1101. Kantola, K., L. Hedman, T. Allander, T. Jartti, P. Lehtinen, O. Ruuskanen, K. Hedman, and M. Soderlund-Venermo. 2008. Serodiagnosis of human bocavirus infection. Clin. Infect. Dis. 46:540–546. Kaplan, N., W. Dove, A. Abu-Zeid, H. Shamoon, S. Abd-Eldayem, and C. A. Hart. 2006. Human bocavirus infection among children, Jordan. Emerg. Infect. Dis. 12:1419–1420. Kesebir, D., M. Vazquez, C. Weibel, E. D. Shapiro, D. Ferguson, M. L. Landry, and J. S. Kahn. 2006. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J. Infect. Dis. 194:1276–1282. Khetsuriani, N., N. N. Kazerouni, D. D. Erdman, X. Lu, S. C. Redd, L. J. Anderson, and W. G. Teague. 2007. Prevalence of viral respiratory tract infections in children with asthma. J. Allergy Clin. Immunol. 119:314–321. Kleines, M., S. Scheithauer, A. Rackowitz, K. Ritter, and M. Hausler. 2007. High prevalence of human bocavirus detected in young children with severe acute lower respiratory tract disease using a standard PCR protocol and a novel real-time PCR protocol. J. Clin. Microbiol. 45:1032–1034. Kramer, A., I. Schwebke, and G. Kampf. 2006. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect. Dis. 6:130. Kupfer, B., J. Vehreschild, O. Cornely, R. Kaiser, G. Plum, S. Viazov, C. Franzen, R. L. Tillmann, A. Simon, A. Muller, and O. Schildgen. 2006. Severe pneumonia and human bocavirus in an adult. Emerg. Infect. Dis. 12:1614–1616. Lee, J. I., J. Y. Chung, T. H. Han, M. O. Song, and E. S. Hwang. 2007. Detection of human bocavirus in children hospitalized because of acute gastroenteritis. J. Infect. Dis. 196:994–997. Lefrere, J. J., A. Servant-Delmas, D. Candotti, M. Mariotti, I. Thomas, Y. Brossard, F. Lefrere, R. Girot, J. P. Allain, and S. Laperche. 2005. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood 106:2890–2895. Lehmann, H., and S. Modrow. 2004. Parvovirus B19—ein ha¨ufig unterscha¨tzter Infektionserreger mit vielen Krankheitsbildern. Monatsschr. Kinderheilkd. 152: 203–214. Lin, F., A. Zeng, N. Yang, H. Lin, E. Yang, S. Wang, D. Pintel, and J. Qiu. 2007. Quantification of human bocavirus in lower respiratory tract infections in China. Infect. Agents Cancer 2:3. Lindblom, A., A. Isa, O. Norbeck, S. Wolf, B. Johansson, K. Broliden, and T. Tolfvenstam. 2005. Slow clearance of human parvovirus B19 viremia following acute infection. Clin. Infect. Dis. 41:1201–1203. Lu, X., M. Chittaganpitch, S. J. Olsen, I. M. Mackay, T. P. Sloots, A. M. Fry, and D. D. Erdman. 2006. Real-time PCR assays for detection of bocavirus in human specimens. J. Clin. Microbiol. 44:3231–3235. Ma, X., R. Endo, N. Ishiguro, T. Ebihara, H. Ishiko, T. Ariga, and H. Kikuta. 2006. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J. Clin. Microbiol. 44:1132–1134. Mackay, I. (ed.). 2007. Real-time PCR in microbiology: from diagnosis to characterisation. Caister Academic Press, Norwich, United Kingdom. Maggi, F., E. Andreoli, M. Pifferi, S. Meschi, J. Rocchi, and M. Bendinelli. 2007. Human bocavirus in Italian patients with respiratory diseases. J. Clin. Virol. 38:321–325. Manning, A., V. Russell, K. Eastick, G. H. Leadbetter, N. Hallam, K. Templeton, and P. Simmonds. 2006. Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J. Infect. Dis. 194:1283–1290. Manning, A., S. J. Willey, J. E. Bell, and P. Simmonds. 2007. Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J. Infect. Dis. 195:1345–1352. McErlean, P., L. A. Shackelton, S. B. Lambert, M. D. Nissen, T. P. Sloots, and I. M. Mackay. 2007. Characterisation of a newly identified human
HBoV: PASSENGER OR PATHOGEN?
52. 53. 54.
55.
56.
57. 58. 59.
60.
61. 62.
63.
64. 65.
66.
67.
68.
69. 70. 71.
72.
73.
74.
75.
76. 77.
78.
79.
303
rhinovirus, HRV-QPM, discovered in infants with bronchiolitis. J. Clin. Virol. 39:67–75. McIntosh, K. 2006. Human bocavirus: developing evidence for pathogenicity. J. Infect. Dis. 194:1197–1199. Modrow, S., and B. Ga ¨rtner. 2006. Parvovirus B19 Infektionen in der ´ rztebl. 103:A2869–A2876. Schwangerschaft. Dtsch. A Monteny, M., H. G. Niesters, H. A. Moll, and M. Y. Berger. 2007. Human bocavirus in febrile children, The Netherlands. Emerg. Infect. Dis. 13:180– 182. Naghipour, M., L. E. Cuevas, T. Bakhshinejad, W. Dove, and C. A. Hart. 2007. Human bocavirus in Iranian children with acute respiratory infections. J. Med. Virol. 79:539–543. Neske, F., K. Blessing, F. Tollmann, J. Schubert, A. Rethwilm, H. W. Kreth, and B. Weissbrich. 2007. Real-time PCR for diagnosis of human bocavirus infections and phylogenetic analysis. J. Clin. Microbiol. 45:2116–2122. Reference deleted. Page, R. D. 1996. TreeView: an application to display phylogenetic trees on personal computers. Comput. Appl. Biosci. 12:357–358. Qu, X. W., Z. J. Duan, Z. Y. Qi, Z. P. Xie, H. C. Gao, W. P. Liu, C. P. Huang, F. W. Peng, L. S. Zheng, and Y. D. Hou. 2007. Human bocavirus infection, People’s Republic of China. Emerg. Infect. Dis. 13:165–168. Regamey, N., U. Frey, C. Deffernez, P. Latzin, and L. Kaiser. 2007. Isolation of human bocavirus from Swiss infants with respiratory infections. Pediatr. Infect. Dis. J. 26:177–179. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406–425. Schenk, T., B. Huck, J. Forster, R. Berner, D. Neumann-Haefelin, and V. Falcone. 2007. Human bocavirus DNA detected by quantitative real-time PCR in two children hospitalized for lower respiratory tract infection. Eur. J. Clin. Microbiol. Infect. Dis. 26:147–149. Schildgen, O., T. Geikowski, T. Glatzel, A. Simon, A. Wilkesmann, M. Roggendorf, S. Viazov, and B. Matz. 2004. New variant of the human metapneumovirus (HMPV) associated with an acute and severe exacerbation of asthma bronchiale. J. Clin. Virol. 31:283–288. Schildgen, O., A. Wilkesmann, and A. Simon. 2006. Wheezing in patients with human metapneumovirus infection. J. Allergy Clin. Immunol. 117:223. Schwartz, D., B. Green, L. E. Carmichael, and C. R. Parrish. 2002. The canine minute virus (minute virus of canines) is a distinct parvovirus that is most similar to bovine parvovirus. Virology 302:219–223. Simon, A., P. Groneck, B. Kupfer, R. Kaiser, G. Plum, R. L. Tillmann, A. Muller, and O. Schildgen. 2007. Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis. J. Infect. 54:e125–e127. Simon, A., K. Khurana, A. Wilkesmann, A. Muller, S. Engelhart, M. Exner, O. Schildgen, A. M. Eis-Hubinger, J. R. Groothuis, and U. Bode. 2006. Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control. Int. J. Hyg. Environ. Health 209: 317–324. Sloots, T. P., P. McErlean, D. J. Speicher, K. E. Arden, M. D. Nissen, and I. M. Mackay. 2006. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J. Clin. Virol. 35:99–102. Smuts, H., and D. Hardie. 2006. Human bocavirus in hospitalized children, South Africa. Emerg. Infect. Dis. 12:1457–1458. Smyth, R. L., and P. J. Openshaw. 2006. Bronchiolitis. Lancet 368:312–322. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876–4882. van der Hoek, L., K. Pyrc, M. F. Jebbink, W. Vermeulen-Oost, R. J. Berkhout, K. C. Wolthers, P. M. Wertheim-van Dillen, J. Kaandorp, J. Spaargaren, and B. Berkhout. 2004. Identification of a new human coronavirus. Nat. Med. 10:368–373. Vicente, D., G. Cilla, M. Montes, E. G. Perez-Yarza, and E. Perez-Trallero. 2007. Human bocavirus, a respiratory and enteric virus. Emerg. Infect. Dis. 13:636–637. Vo ¨lz, S., O. Schildgen, D. Klinkenberg, V. Ditt, A. Mu ¨ller, R. L. Tillmann, B. Kupfer, U. Bode, M. J. Lentze, and A. Simon. 2007. Prospective study of human bocavirus (HBoV) infection in a pediatric university hospital in Germany 2005/2006. J. Clin. Virol. 40:229–235. Weigl, J. A., W. Puppe, and H. J. Schmitt. 2003. Can respiratory syncytial virus etiology be diagnosed clinically? A hospital-based case-control study in children under two years of age. Eur. J. Epidemiol. 18:431–439. Weinstein, M. 2005. Atypical presentation of parvovirus infection. Pediatr. Infect. Dis. J. 24:283–284. Weissbrich, B., F. Neske, J. Schubert, F. Tollmann, K. Blath, K. Blessing, and H. W. Kreth. 2006. Frequent detection of bocavirus DNA in German children with respiratory tract infections. BMC Infect. Dis. 6:109. Wilkesmann, A., O. Schildgen, A. M. Eis-Hubinger, T. Geikowski, T. Glatzel, M. J. Lentze, U. Bode, and A. Simon. 2006. Human metapneumovirus infections cause similar symptoms and clinical severity as respiratory syncytial virus infections. Eur. J. Pediatr. 165:467–475. Wilkesmann, A., O. Schildgen, A. M. Eis-Hubinger, M. J. Lentze, U. Bode,
304
SCHILDGEN ET AL.
and A. Simon. 2007. Human metapneumovirus in hospitalized children—a review. Klin. Padiatr. 219:58–65. (In German.) 80. Williams, J. V. 2005. The clinical presentation and outcomes of children infected with newly identified respiratory tract viruses. Infect. Dis. Clin. N. Am. 19:569–584. 81. Williams, J. V., P. A. Harris, S. J. Tollefson, L. L. Halburnt-Rush, J. M. Pingsterhaus, K. M. Edwards, P. F. Wright, and J. E. Crowe, Jr. 2004. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N. Engl. J. Med. 350:443–450. 82. Woo, P. C., S. K. Lau, C. M. Chu, K. H. Chan, H. W. Tsoi, Y. Huang, B. H. Wong, R. W. Poon, J. J. Cai, W. K. Luk, L. L. Poon, S. S. Wong, Y. Guan, J. S. Peiris, and K. Y. Yuen. 2005. Characterization and complete genome se-
CLIN. MICROBIOL. REV. quence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79:884–895. 83. Young, N. S., and K. E. Brown. 2004. Parvovirus B19. N. Engl. J. Med. 350:586–597. 84. Zharkikh, A., and W. H. Li. 1995. Estimation of confidence in phylogeny: the complete-and-partial bootstrap technique. Mol. Phylogenet. Evol. 4:44–63. 85. Zhi, N., I. P. Mills, J. Lu, S. Wong, C. Filippone, and K. E. Brown. 2006. Molecular and functional analyses of a human parvovirus B19 infectious clone demonstrates essential roles for NS1, VP1, and the 11-kilodalton protein in virus replication and infectivity. J. Virol. 80:5941–5950.
